Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

4(57.1%)

N/A

1(14.3%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 3(4)

N/A(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04258943Phase 1Active Not Recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Role: collaborator

NCT01949129Phase 2Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT00550992Not ApplicableUnknown

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Role: lead

NCT00015873Phase 3Completed

Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia

Role: lead

NCT00379457Phase 3Unknown

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Role: collaborator

NCT00334854Phase 3Unknown

Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

Role: collaborator

NCT01476462Completed

Second Malignant Neoplasms After Childhood ALL Therapy

Role: collaborator

NCT00186966Phase 3Completed

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

Role: lead

All 8 trials loaded